Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 25Radiotherapy 16Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5palbociclib 4Radiation 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3abemaciclib 3X-Rays 3Vincristine 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × peposertib × Sarcoma × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡